Henri Huttunen, Chief Scientific Officer of Herantis Pharma, was interviewed by Antti 
Topics:
(00:00) Introduction
(00:09) Phase 2 study
(00:55) Endpoint
(02:05) Digital tools
(03:10) Secondary endpoints
(03:50) 100-patient study
(06:23) Study timeline
(07:29) Pros and cons of the study
(09:18) Role of the FDA
(11:04) Post-study period
(12:25) Phase 3 / Phase 2b
(13:29) Financing situation